Substituted phenazines and methods of treating cancer and bacterial diseases

Inventors

Rongved, Pål • ÅSTRAND, Ove Alexander Høgmoen • VIKTORSSON, Elvar Ørn • SAMUELSON, Ørjan • Heikal, Adam • LØCHEN ØKSTAD, Ole Andreas • KILDAHL-ANDERSEN, Geir

Assignees

AdjuTec Pharma AS

Abstract

A combination product comprising a carbapenem and a compound of formula (I′), or a pharmaceutically acceptable salt thereof: a pharmaceutical composition comprising the combination product; and methods of treating bacterial or fungal infections using the combination product and pharmaceutical composition.

Core Innovation

The invention provides a combination product that includes meropenem and a compound defined by a specified formula, or a pharmaceutically acceptable salt thereof. The specification describes multiple families of substituted aromatic compounds using general formulas and broad structural definitions of variables that define the compound families associated with the formula representations.

The document further describes possible ester, carbonate ester, and carbamate forms, and cleavable group Z that is tunable and cleavable in vivo by hydrolytic and/or enzymatic cleavage. The cleavable group Z is stated to regenerate parent groups, including groups such as —OH, —COOH, and —CONH2, and targeting moieties may be incorporated into Z.

Phenazine bioactivity is discussed as being associated with metal-ion binding and ionophore activity, and the approach addresses limitations of prior phenazine/iodinin derivatives, including low solubility for injection, limited synthetic availability, non-selective biodistribution, and limited or missing N-oxide functionality. The therapeutic use is connected to the combination-product framework in which meropenem is combined with the formula-defined phenazine-derived compounds or their pharmaceutically acceptable salts.

Claims Coverage

The provided claim set includes one independent claim covering the combination product and multiple dependent claims that refine it by formulation and by therapeutic methods for bacterial or fungal infections. The core inventive feature is the pairing of meropenem with a formula-defined compound, with dependent claims adding a pharmaceutically acceptable carrier or excipient and administration of a therapeutically effective amount.

The claims cover a combination product defined by meropenem plus a formula-defined compound, or a pharmaceutically acceptable salt. Dependent claims further cover pharmaceutical compositions that include a pharmaceutically acceptable carrier or excipient and methods of treating bacterial or fungal infections by administering a therapeutically effective amount, including narrowing to infections caused by microorganisms selected from the named list.

Stated Advantages

Documented Applications